Table of Content

1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SEGMENTATION
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
          TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.6 SCOPE-RELATED LIMITATIONS 
    1.7 STAKEHOLDERS 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION
          FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET (2021)
          FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027)
          FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 12 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 13 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 STUDY ASSUMPTIONS 
    2.6 METHODOLOGY-RELATED LIMITATIONS 
    2.7 RISK ASSESSMENT 
          TABLE 2 RISK ASSESSMENT: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 14 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 GEOGRAPHIC SNAPSHOT OF ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET OVERVIEW 
          FIGURE 18 INCREASING USE OF ENDOSCOPY IN DETECTION AND TREATMENT PROCEDURES TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT AND COUNTRY 
          FIGURE 19 GASTROSCOPES AND COLONOSCOPES HELD LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
    4.3 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: GEOGRAPHIC MIX 
          FIGURE 20 MARKET IN ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
    4.4 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: REGIONAL MIX 
          FIGURE 21 NORTH AMERICA TO BE LARGEST MARKET FOR ENDOSCOPIC SUBMUCOSAL DISSECTION PRODUCTS THROUGHOUT FORECAST PERIOD
    4.5 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 52)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing use of endoscopy in detection and treatment procedures
                    5.2.1.2 Rising prevalence of cancer
                                FIGURE 24 GLOBAL CANCER INCIDENCE, 2008–2030
                    5.2.1.3 Growing geriatric population
                                FIGURE 25 SHARE OF GERIATRIC POPULATION, BY REGION (2010–2030)
                                TABLE 3 GLOBAL CANCER INCIDENCE FOR GERIATRIC POPULATION (65–85+), 2020 VS. 2040
           5.2.2 RESTRAINTS
                    5.2.2.1 Dearth of skilled professionals
                    5.2.2.2 High overhead cost of ESD procedures with limited reimbursements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing demand for minimally invasive procedures
                    5.2.3.2 Growing investments in research and development of endoscopy technology
                                TABLE 4 MAJOR DEVELOPMENTS
                    5.2.3.3 Expected increase in adoption of and preference for endoscopic submucosal dissection procedures in developing countries
           5.2.4 CHALLENGES
                    5.2.4.1 Higher rate of complications
                    5.2.4.2 Risk of post-operative infection
    5.3 INDUSTRY TRENDS 
           5.3.1 ADVANCES IN TRACTION METHODS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION
           5.3.2 ROBOT-ASSISTED ENDOSCOPIC SUBMUCOSAL DISSECTION
    5.4 REGULATORY ANALYSIS 
           5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.4.2 NORTH AMERICA
                    5.4.2.1 US
                    5.4.2.2 Canada
           5.4.3 EUROPE
                    5.4.3.1 Germany
                    5.4.3.2 France
                    5.4.3.3 UK
                    5.4.3.4 Italy
    5.5 ECOSYSTEM MARKET MAP 
          FIGURE 26 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: ECOSYSTEM MARKET MAP
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 27 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: VALUE CHAIN ANALYSIS
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
                    5.7.1.1 High capital requirement
                    5.7.1.2 High preference for products from well-established brands
           5.7.2 THREAT OF SUBSTITUTES
                    5.7.2.1 Presence of substitute therapies for endoscopic submucosal dissection
           5.7.3 BARGAINING POWER OF SUPPLIERS
                    5.7.3.1 Presence of several raw material suppliers
                    5.7.3.2 Supplier switching cost
           5.7.4 BARGAINING POWER OF BUYERS
                    5.7.4.1 Limited number of companies offering premium products at global level
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
                    5.7.5.1 Increasing demand for high-quality and innovative products
                    5.7.5.2 Lucrative growth potential in emerging markets
    5.8 INDICATIVE PRICING MODEL ANALYSIS 
          TABLE 9 AVERAGE SELLING PRICE, BY PRODUCT (USD)
    5.9 PATENT ANALYSIS 
           5.9.1 PATENT PUBLICATION TRENDS FOR ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
                    FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, 2015–2022
           5.9.2 TOP APPLICANTS (COMPANIES) FOR PATENTS RELATED TO ENDOSCOPIC SUBMUCOSAL DISSECTION DEVICES AND MATERIALS
                    FIGURE 29 TOP COMPANIES THAT APPLIED FOR PATENTS RELATED TO ENDOSCOPIC SUBMUCOSAL DISSECTION DEVICES AND MATERIALS, 2015–2022
           5.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
                    FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR PATENTS IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, 2015–2022
    5.10 SUPPLY CHAIN ANALYSIS 
          FIGURE 31 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: STAKEHOLDERS IN SUPPLY CHAIN
    5.11 KEY CONFERENCES AND EVENTS DURING 2022–2023 
           TABLE 10 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
                     TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
           5.12.2 BUYING CRITERIA
                     FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
                     TABLE 12 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
6 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT (Page No. - 77)
    6.1 INTRODUCTION 
          TABLE 13 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 GASTROSCOPES AND COLONOSCOPES 
           6.2.1 RISE IN COLON CANCER INCIDENCE TO DRIVE GROWTH
                    TABLE 14 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR GASTROSCOPES AND COLONOSCOPES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 KNIVES 
           6.3.1 IMPROVED EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF KNIVES TO DRIVE MARKET GROWTH
                    TABLE 15 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR KNIVES, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 INJECTION AGENTS 
           6.4.1 NEED FOR LOW-COST INJECTION AGENTS TO BOOST GROWTH
                    TABLE 16 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR INJECTION AGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 TISSUE RETRACTORS 
           6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO AID ADOPTION OF TISSUE RETRACTORS
                    TABLE 17 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR TISSUE RETRACTORS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.6 GRASPERS/CLIPS 
           6.6.1 PATIENT SAFETY AND HIGH PRECISION OFFERED BY GRASPERS TO DRIVE THEIR DEMAND
                    TABLE 18 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR GRASPERS/CLIPS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.7 OTHER PRODUCTS 
          TABLE 19 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION)
7 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION (Page No. - 85)
    7.1 INTRODUCTION 
          TABLE 20 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 21 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2021 (NUMBER OF PROCEDURES)
    7.2 STOMACH CANCER 
           7.2.1 STOMACH CANCER OR GASTRIC CANCER ASSOCIATED WITH SIGNIFICANT PROPORTION OF ALL CANCER DEATHS
                    TABLE 22 ESTIMATED NUMBER OF NEW CASES OF STOMACH CANCER, BY REGION (2020–2040)
                    TABLE 23 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR STOMACH CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 24 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR STOMACH CANCER, BY REGION, 2021 (NUMBER OF PROCEDURES)
    7.3 COLON CANCER 
           7.3.1 COLON CANCER IS THIRD-MOST-COMMON CANCER AND SECOND-LEADING CAUSE OF CANCER DEATHS WORLDWIDE
                    TABLE 25 ESTIMATED NUMBER OF NEW CASES OF COLON CANCER, BY REGION (2020–2040)
                    TABLE 26 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR COLON CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 27 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR COLON CANCER, BY REGION, 2021 (NUMBER OF PROCEDURES)
    7.4 ESOPHAGEAL CANCER 
           7.4.1 GROWING PREVALENCE OF ESOPHAGEAL CANCER ATTRIBUTED TO EXCESS TOBACCO AND ALCOHOL USE
                    TABLE 28 ESTIMATED NUMBER OF NEW CASES OF ESOPHAGEAL CANCER, BY REGION (2020–2040)
                    TABLE 29 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR ESOPHAGEAL CANCER, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 30 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR ESOPHAGEAL CANCER, BY REGION, 2021 (NUMBER OF PROCEDURES)
8 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER (Page No. - 93)
    8.1 INTRODUCTION 
          TABLE 31 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 HOSPITALS 
           8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES AND ESD PROCEDURES TO SUPPORT GROWTH
                    TABLE 32 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 SPECIALTY CLINICS 
           8.3.1 TRANSITION FROM HOSPITAL-BASED PROCEDURES TO CLINIC-BASED PROCEDURES TO BOOST GROWTH
                    TABLE 33 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 AMBULATORY SURGICAL CENTERS 
           8.4.1 GROWTH IN ASC SEGMENT DRIVEN BY INCREASING NUMBER OF OUTPATIENT VISITS
                    TABLE 34 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 OTHER END USERS 
          TABLE 35 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
9 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION (Page No. - 100)
    9.1 INTRODUCTION 
          FIGURE 34 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          TABLE 36 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 35 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SNAPSHOT
          TABLE 37 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 38 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 39 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 40 NORTH AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US is largest market for endoscopic submucosal dissection products
                                TABLE 41 US: MACROECONOMIC INDICATORS
                                TABLE 42 US: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 43 US: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 44 US: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Slower healthcare development in Canada over past decade to restrain growth
                                TABLE 45 AGE-STANDARDIZED INCIDENCE RATES (ASIR) FOR SELECTED CANCERS IN MEN AND WOMEN IN CANADA, 2020 VS. 2040
                                TABLE 46 CANADA: MACROECONOMIC INDICATORS
                                TABLE 47 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 48 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 49 CANADA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE 
          TABLE 50 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 51 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 52 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 53 EUROPE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany to account for largest share of European market
                                TABLE 54 GERMANY: MACROECONOMIC INDICATORS
                                TABLE 55 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 56 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 57 GERMANY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 High-quality healthcare system offering coverage to all citizens to support market growth
                                TABLE 58 FRANCE: MACROECONOMIC INDICATORS
                                TABLE 59 FRANCE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 60 FRANCE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 61 FRANCE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Investments by hospitals to purchase new and advanced endoscopic submucosal dissection equipment to propel market
                                TABLE 62 UK: MACROECONOMIC INDICATORS
                                TABLE 63 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 64 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 65 UK: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Receptivity of government toward high-quality and technologically advanced equipment to foster growth
                                TABLE 66 ITALY: MACROECONOMIC INDICATORS
                                TABLE 67 ITALY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 68 ITALY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 69 ITALY: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising prevalence of cancer to drive market growth
                                TABLE 70 SPAIN: MACROECONOMIC INDICATORS
                                TABLE 71 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 72 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 73 SPAIN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 74 ROE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 75 ROE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 76 ROE: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 36 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SNAPSHOT
          TABLE 77 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 78 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
          TABLE 79 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
          TABLE 80 ASIA PACIFIC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Supportive medical device reimbursement policies to drive market growth
                                TABLE 81 JAPAN: MACROECONOMIC INDICATORS
                                TABLE 82 JAPAN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 83 JAPAN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 84 JAPAN: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 Large patient population and strong need for healthcare infrastructure improvements to boost market growth
                                TABLE 85 CHINA: MACROECONOMIC INDICATORS
                                TABLE 86 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 87 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 88 CHINA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Favorable government initiatives for healthcare infrastructure improvements to support market growth
                                TABLE 89 INDIA: MACROECONOMIC INDICATORS
                                TABLE 90 INDIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                TABLE 91 INDIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                                TABLE 92 INDIA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 93 ROAPAC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 94 ROAPAC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 95 ROAPAC: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 LATIN AMERICA 
           9.5.1 INCREASING PURCHASING POWER AND HEALTHCARE AFFORDABILITY WILL FAVOR MARKET GROWTH
                    TABLE 96 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 97 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 98 LATIN AMERICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.6 MIDDLE EAST AND AFRICA 
           9.6.1 HEALTHCARE INFRASTRUCTURAL ADVANCEMENTS WILL CREATE NEED FOR HOSPITAL EQUIPMENT AND MEDICAL DEVICES
                    TABLE 99 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                    TABLE 100 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY INDICATION, 2020–2027 (USD MILLION)
                    TABLE 101 MIDDLE EAST & AFRICA: ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET, BY END USER, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 138)
     10.1 INTRODUCTION 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
     10.3 REVENUE ANALYSIS OF KEY MARKET PLAYERS 
            FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS OPERATING IN ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET
     10.4 MARKET SHARE ANALYSIS 
            FIGURE 38 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET SHARE, BY KEY PLAYER (2021)
     10.5 COMPANY FOOTPRINT ANALYSIS 
             10.5.1 FOOTPRINT OF COMPANIES, BY PRODUCT
             10.5.2 FOOTPRINT OF COMPANIES, BY END USER
             10.5.3 FOOTPRINT OF COMPANIES, BY REGION
     10.6 COMPANY EVALUATION MATRIX 
             10.6.1 STARS
             10.6.2 EMERGING LEADERS
             10.6.3 PERVASIVE PLAYERS
             10.6.4 PARTICIPANTS
                        FIGURE 39 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: COMPANY EVALUATION MATRIX
     10.7 COMPETITIVE BENCHMARKING 
             TABLE 102 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: KEY START-UPS/SMES
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES
                        TABLE 103 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: PRODUCT LAUNCHES (JANUARY 2019–DECEMBER 2022)
             10.8.2 DEALS
                        TABLE 104 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: DEALS (JANUARY 2019–DECEMBER 2022)
             10.8.3 OTHER DEVELOPMENTS
                        TABLE 105 ENDOSCOPIC SUBMUCOSAL DISSECTION MARKET: OTHER DEVELOPMENTS (JANUARY 2019–DECEMBER 2022)
11 COMPANY PROFILES (Page No. - 150)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     11.1 KEY PLAYERS 
             11.1.1 OLYMPUS CORPORATION
                        TABLE 106 OLYMPUS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2022)
             11.1.2 FUJIFILM HOLDINGS CORPORATION
                        TABLE 107 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2021)
             11.1.3 BOSTON SCIENTIFIC CORPORATION
                        TABLE 108 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
                        FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2021)
             11.1.4 MEDTRONIC
                        TABLE 109 MEDTRONIC: BUSINESS OVERVIEW
                        FIGURE 43 COMPANY SNAPSHOT: MEDTRONIC (2022)
             11.1.5 SUMITOMO BAKELITE CO., LTD.
                        TABLE 110 SUMITOMO BAKELITE CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 44 COMPANY SNAPSHOT: SUMITOMO BAKELITE CO., LTD. (2021)
             11.1.6 CREO MEDICAL GROUP PLC
                        TABLE 111 CREO MEDICAL GROUP PLC: BUSINESS OVERVIEW
                        FIGURE 45 COMPANY SNAPSHOT: CREO MEDICAL GROUP PLC (2021)
             11.1.7 HOYA CORPORATION
                        TABLE 112 HOYA CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2022)
             11.1.8 CONMED CORPORATION
                        TABLE 113 CONMED CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 COMPANY SNAPSHOT: CONMED CORPORATION (2021)
             11.1.9 STERIS PLC
                        TABLE 114 STERIS PLC: BUSINESS OVERVIEW
                        FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2022)
             11.1.10 MTW ENDOSKOPIE MANUFAKTUR
                        TABLE 115 MTW ENDOSKOPIE MANUFAKTUR: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 OVESCO ENDOSCOPY AG
                        TABLE 116 OVESCO ENDOSCOPY AG: BUSINESS OVERVIEW
             11.2.2 ZEON MEDICAL INC.
                        TABLE 117 ZEON MEDICAL INC.: BUSINESS OVERVIEW
             11.2.3 MICRO-TECH ENDOSCOPY
                        TABLE 118 MICRO-TECH ENDOSCOPY: BUSINESS OVERVIEW
             11.2.4 KARL STORZ SE & CO. KG
                        TABLE 119 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW
             11.2.5 COOK MEDICAL
                        TABLE 120 COOK MEDICAL: BUSINESS OVERVIEW
             11.2.6 LEO MEDICAL CO., LTD.
                        TABLE 121 LEO MEDICAL CO., LTD.: BUSINESS OVERVIEW
             11.2.7 ERBE ELEKTROMEDIZIN GMBH
                        TABLE 122 ERBE ELEKTROMEDIZIN GMBH: BUSINESS OVERVIEW
             11.2.8 TAEWOONG MEDICAL CO., LTD.
                        TABLE 123 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW
             11.2.9 DCC HEALTHCARE LIMITED
                        TABLE 124 DCC HEALTHCARE LIMITED: BUSINESS OVERVIEW
             11.2.10 KOSSEN CO., LTD.
                        TABLE 125 KOSSEN CO., LTD.: BUSINESS OVERVIEW
             11.2.11 INNOVAMEDICA S.P.A.
                        TABLE 126 INNOVAMEDICA S.P.A.: BUSINESS OVERVIEW
             11.2.12 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.
                        TABLE 127 JIANGSU VEDKANG MEDICAL SCIENCE AND TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
             11.2.13 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.
                        TABLE 128 HANGZHOU AGS MEDICAL TECHNOLOGICAL CO., LTD.: BUSINESS OVERVIEW
             11.2.14 BEIJING ZKSK TECHNOLOGY CO., LTD.
                        TABLE 129 BEIJING ZKSK TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 194)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS